Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;25(1):5-13.
doi: 10.1111/cns.13050. Epub 2018 Aug 12.

Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?

Affiliations
Review

Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?

Sara Merlo et al. CNS Neurosci Ther. 2019 Jan.

Abstract

Alzheimer's disease (AD) is characterized by extensive neurodegeneration and inflammation in selective brain areas, linked to severely disabling cognitive deficits. Before full manifestation, different stages appear with progressively increased brain pathology and cognitive impairment. This significantly extends the time lag between initial molecular triggers and appearance of detectable symptoms. Notably, a number of studies in the last decade have revealed that in the early stage of mild cognitive impairment, events that appear in contrast with neuronal distress may occur. These have been reproduced in vitro and in animal models and include increase in synaptic elements, increase in synaptic and metabolic activity, enhancement of neurotrophic milieu and changes in glial cell reactivity and inflammation. They have been interpreted as compensatory responses that could either delay disease progression or, in the long run, result detrimental. For this reason, these mechanisms define a new and previously undervalued window of opportunity for intervention. Their importance resides especially in their early appearance. Directing efforts to better characterize this stage, in order to identify new pharmacological targets, is an exciting new avenue to future advances in AD research.

Keywords: beta-amyloid; cognitive impairment; compensation; glial reactivity; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Compensation as a neuroprotective strategy in AD. A, As Aβ/tau brain pathology increases, compensatory events come into play to counteract the decline in neuronal functions and confer increased tolerance to brain pathology. Inability to adopt compensatory responses results in an earlier decline. B, Compensatory events evenly balance pathological ones in early prodromal stages of disease, but they begin to fail due to overload of pathology in MCI until they are no longer able to efficiently contrast pathology, or even become detrimental, in severe AD

Similar articles

Cited by

References

    1. Cline EN, Bicca MA, Viola KL, et al. The amyloid‐beta oligomer hypothesis: beginning of the third decade. J Alzheimers Dis. 2018;64(s1):S567‐S610. - PMC - PubMed
    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595‐608. - PMC - PubMed
    1. Chong FP, Ng KY, Koh RY, et al. Tau proteins and tauopathies in alzheimer's disease. Cell Mol Neurobiol. 2018;38(5):965‐980. - PMC - PubMed
    1. Walsh DM, Selkoe DJ. A beta oligomers ‐ a decade of discovery. J Neurochem. 2007;101(5):1172‐1184. - PubMed
    1. Park J, Jang M, Chang S. Deleterious effects of soluble amyloid‐beta oligomers on multiple steps of synaptic vesicle trafficking. Neurobiol Dis. 2013;55:129‐139. - PubMed

Publication types